Radiation Biology & dna rEPAIR

SCIENTIFIC ACCOMPLISHMENTS

The RBDR program has continued to build on our previous success, as documented by our recent scientific accomplishments:

Raf-1-related findings

Identification of Raf-1–related novel gene products that may be novel targets for radiosensitization (Mewani et al., Int J Mol Med, 2006).
Completion of phase 1 study of liposome-encapsulated c-raf antisense oligonucleotides (LErafAON) in combination with radiation therapy (Dritschilo et al., Clin Cancer Res, 2006).

NF-κB and HDAC inhibition related findings

Demonstration that NF-kB inhibition sensitizes transformed prostate cancer cells to HDAC inhibition (Carcinogenesis, 27: 2258-2268, 2006).

PARP-related findings

PARP-1 binds to gene promoter sequences, including its own 5'-flanking region both in vitro and in vivo, and regulates transcription (Amiri et al., Oncogene 25: 7714-7722, 2006).

Inhibition of Ewing’s malignant phenotype

Preclinical studies demonstrate effectiveness of AS-ODNs specific for the EWS/FLI-1 gene to inhibit growth, induce apoptosis, and sensitize Ewing’s sarcoma to chemo- and radio-therapeutic treatments (Mateo-Lozano et al., Clin Cancer Res 12: 6781-6790, 2006).
Identification of Caveolin-1 (CAV1) as an EWS/FLI-1 target and a determinant of Ewing’s sarcoma cells response to chemo- and radio-therapeutic treatments (Tirado et al., Cancer Res 66: 9937-9947, 2006).